Carnegie Capital Asset Management, LLC Intellia Therapeutics, Inc. Transaction History

Carnegie Capital Asset Management, LLC

  • $3.34 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 13, 2020
SELL
$10.43 - $17.67 $365,050 - $618,450
-35,000 Closed
0 $0
Q3 2019

Nov 20, 2019
SELL
$13.07 - $18.51 $326,750 - $462,750
-25,000 Reduced 41.67%
35,000 $467,000
Q2 2019

Jul 24, 2019
BUY
$13.88 - $18.41 $832,800 - $1.1 Million
60,000 New
60,000 $982,000

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Carnegie Capital Asset Management, LLC Portfolio

Follow Carnegie Capital Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carnegie Capital Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Carnegie Capital Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email